Normal human uterus is colonised by clones with cancer-driving mutations that arise early in life, study finds
Hope that insights into earliest stages of uterine cancer development will help to tackle one of most common female cancers
Many cells in the inner lining of the uterus carry ‘cancer-driving’ mutations that frequently arise early in life, report scientists from the Wellcome Sanger Institute, the University of Cambridge and their collaborators. The research team conducted whole-genome sequencing of healthy human endometrium, providing a comprehensive overview of the rates and patterns of DNA changes in this tissue.
The work, published today (22 April) in Nature, provides insights into the earliest stages of uterine cancer development.
The endometrium is the inner part of the uterus, more commonly known as the womb lining. It is regulated by hormones such as oestrogen and progesterone and enters different states during childhood, reproductive years, pregnancy and after menopause.
Uterine cancer is the fourth most common cancer in women in the UK, accounting for five per cent of all new female cancer cases. Around 9,400 new cases are diagnosed every year, leading to the death of 2,300 women. Most cases occur in the seventh and eighth decades. Since the early 1990s, the incidence of uterine cancer has risen by 55 per cent in the UK*.
All cancers occur due to changes in DNA, known as somatic mutations, which continuously occur in all of our cells throughout life. A tiny fraction of these somatic mutations can contribute to a normal cell turning into a cancer cell and are known as ‘driver’ mutations, which occur within a subset of ‘cancer’ genes.
This study used whole-genome sequencing to better understand the genetic changes in healthy endometrial tissue. The team developed technology to sequence the genomes of small numbers of cells from individual glands in the endometrial epithelium, the tissue layer that sheds and regenerates during a woman’s menstrual cycle.
Laser-capture microscopy was used to isolate 292 endometrial glands from womb tissue samples donated by 28 women aged 19 to 81 years**, before DNA from each gland was whole-genome sequenced. The team then searched for somatic mutations in each gland by comparing them with whole genome sequences from other tissues from the same individuals.
The researchers found that a high proportion of cells carried driver mutations, even though they appeared completely normal under the microscope. Many of these driver mutations appear to have arisen early in life, in many cases during childhood.
“Human endometrium is a highly dynamic tissue that undergoes numerous cycles of remodelling during female reproductive years. We identified frequent cancer driver mutations in normal endometrium and showed that many such events had occurred early in life, in some cases even before adolescence. Over time, these mutant stem cells accumulate further driver mutations.”
Dr Luiza Moore, the lead researcher based at the Wellcome Sanger Institute
Despite the early occurrence of the first cancer-driver mutations, it takes several decades for a cell to accumulate the remaining drivers that will lead to invasive cancer. Typically, three to six driver mutations in the same cell are required for cancer to develop. As such, the vast majority of normal cells with driver mutations never convert into invasive cancers. When an invasive cancer develops, it may have been silently evolving within us for most of our lifetime.
“Incidence of uterine cancers have been steadily rising in the UK for several decades, so knowing when and why genetic changes linked to cancer occur will be vital in helping to reverse this trend. This research is an important step and wouldn’t have been possible without the individuals who gifted precious samples for this study, including transplant donors and their families.”
Dr Kourosh Saeb-Parsy, University of Cambridge and Director of the Cambridge Biorepository for Translational Medicine (CBTM)
“New technologies and approaches to investigating DNA mutations in normal tissues are providing profound insights into the procession of genetic changes that convert a normal cell into a cancer cell. The results indicate that, although most cancers occur at relatively advanced ages, the genetic changes that underlie them may have started early in life and we may have been incubating the developing cancer for most of our lifetime.”
Professor Sir Mike Stratton, Director of the Wellcome Sanger Institute
*Information and statistics about uterine cancers are available from the Cancer Research UK website: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/uterine-cancer
**The Cambridge Biorepository for Translational Medicine (CBTM) supports research requiring human tissue that aims to improve healthcare for patients. Tissue samples used in this study were from post-mortem or transplant donors, with samples also coming from biopsies for non-endometrial diseases. The authors would like to acknowledge all those who provided tissue used in this study, one third of whom were post-mortem or transplant donors. Their generous contribution is incredibly important for facilitating research that will help to improve the quality of healthcare for patients. https://www.cbtm.group.cam.ac.uk/aboutus
Luiza Moore, Daniel Leongamornlert and Tim H. H. Coorens et al. (2020). The mutational landscape of normal human endometrial epithelium. Nature. DOI: 10.1038/s41586-020-2214-z
This work was supported by Wellcome.
The mission of the University of Cambridge is to contribute to society through the pursuit of education, learning and research at the highest international levels of excellence. To date, 107 affiliates of the University have won the Nobel Prize.
Founded in 1209, the University comprises 31 autonomous Colleges, which admit undergraduates and provide small-group tuition, and 150 departments, faculties and institutions. Cambridge is a global university. Its 19,000 student body includes 3,700 international students from 120 countries. Cambridge researchers collaborate with colleagues worldwide, and the University has established larger-scale partnerships in Asia, Africa and America.
The University sits at the heart of the ‘Cambridge cluster’, which employs 60,000 people and has in excess of £12 billion in turnover generated annually by the 4,700 knowledge-intensive firms in and around the city. The city publishes 341 patents per 100,000 residents. www.cam.ac.uk
The Wellcome Sanger Institute is a world leading genomics research centre. We undertake large-scale research that forms the foundations of knowledge in biology and medicine. We are open and collaborative; our data, results, tools and technologies are shared across the globe to advance science. Our ambition is vast – we take on projects that are not possible anywhere else. We use the power of genome sequencing to understand and harness the information in DNA. Funded by Wellcome, we have the freedom and support to push the boundaries of genomics. Our findings are used to improve health and to understand life on Earth. Find out more at www.sanger.ac.uk or follow us on Twitter, Facebook, LinkedIn and on our Blog.
Wellcome exists to improve health by helping great ideas to thrive. We support researchers, we take on big health challenges, we campaign for better science, and we help everyone get involved with science and health research. We are a politically and financially independent foundation. https://wellcome.org/
Related blog posts
5 Jan 2020
“If you know, there is a Nobel prize for you!” – Searching for the causes of cancer in Czechia
In a study spanning five continents, researchers are hunting for tell-tale ‘signatures’ left in DNA by the unknown causes of cancer.
Giants in genomics: Mike Stratton
Professor Sir Mike Stratton is the director of the Wellcome Trust Sanger Institute and co-leader of the Cancer Genome Project.
16 Apr 2021
Genetic variants identified that impact immune cells' functioning
Researchers have combined genome-wide sequencing and functional profiling of immune cells to understand more about the impact of genetic variants on ...
12 Apr 2021
New genetic drug target for treatment resistant colorectal cancer
Researchers have identified a new potential drug target for treating some types of advanced colorectal cancers.